WuXi PharmaTech

WuXi NextCODE partners with hospital

Friday, September 25, 2015

WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai, have partnered to advance precision medicine in China. It brings WuXi NextCODE’s genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to immediately begin delivering benefits to thousands of rare disease patients across China.

[Read More]

Johnson & Johnson Innovation inks 17 collaborations

Friday, June 12, 2015

Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.

[Read More]

WuXi AppTec partners with Fudan University, CICGD

Monday, June 8, 2015

Global CRO WuXi AppTec has partnered with China’s Fudan University to bring WuXi NextCODE‘s population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis and treatment of rare inherited diseases and malignant tumors.

[Read More]

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

[Read More]

WuXi PharmaTech forms special committee to evaluate non-binding proposal

Friday, May 15, 2015

Global CRO WuXi PharmaTech has announced that, in response to a preliminary non-binding proposal letter, dated April 29, received by the company’s board of directors from Dr. Ge Li, founder, chairman and CEO of the company, and Ally Bridge Group Capital Partners to acquire the company in a “going private” transaction, the board has formed a special committee of independent directors consisting of Xuesong (Jeff) Leng, William R. Keller and Walter T. Kwauk to evaluate the proposed transaction.  

[Read More]

WuXi NextCODE Genomics, DNAnexus partner

Friday, April 24, 2015

WuXi NextCODE Genomics, a subsidiary of WuXi PharmaTech, an open-access R&D capability and technology platform company, and DNAnexus, an cloud-based genome informatics and data management company, have formed a strategic alliance that aims to accelerate the use of genomics to benefit patients worldwide.

[Read More]